PARIS, France – The multidisciplinary European consortium MARVAX will receive 7.4 million euros over the next four years for the research and development of vaccines against Marburg viruses. Researchers from France, Spain and Germany will develop novel vaccine candidates, which will be tested in preclinical animal models and bring them...
Latest News
Shangai, China and TEL AVIV, Israel and ATHENS, Greece and ZURICH, Switzerland — The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world, has expanded its reach to include the...
The Cayman Islands joins the United Nations in observing the first annual Sickle Cell Disease World Day on Friday, 19 June. The worldwide event will raise awareness of the disease, and follows a United Nations General Assembly resolution adopted in December 2008 that recognizes sickle cell disease as a public...
Melbourne, Australia – Researchers at St Vincent’s Institute of Medical Research (SVI) in Melbourne have shown that a commonly prescribed rheumatoid arthritis drug can suppress the progression of type 1 diabetes. The world-first human trial, published today in the New England Journal of Medicine and led by SVI’s Professor Thomas...
Manchester, England – In a momentous landmark for medical research, UK Biobank has today unveiled incredible new data from whole genome sequencing of its half a million participants. This is set to drive the discovery of new diagnostics, treatments and cures and, uniquely, is available to approved researchers worldwide, via...
Full-service contract research organisation (CRO) Worldwide Clinical Trials has partnered with Every Cure to expedite the discovery of treatments for patients with rare diseases. Worldwide will serve as a drug development and clinical trial partner to Every Cure, a non-profit organisation that aims to ‘unlock the full potential of existing...
ST. LOUIS & SAN DIEGO – Wugen, Inc., a clinical stage biotechnology company developing a pipeline of off-the-shelf cell therapies, today announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate...
UPTON, NY – Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory have demonstrated a new, highly detailed x-ray imaging technique that could be developed into a method for early diagnosis of Alzheimer’s disease. The technique has previously been used to look at tumors in breast tissue and...
BOSTON, Mass. — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM...
X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”).